GGrantIndex
← Leaderboards

Michael B Lilly

Loma Linda University

Google Scholar ↗PubMed ↗ORCID ↗
$4,083,409
Attributed
$6,079,998
Total exposure
7
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.7M · FY2005–22
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$14,088,478 · 8

By mechanism

U54$8,229,596 · 2
K12$2,964,115 · 1
R44$1,977,275 · 1
R01$370,628 · 1
R21$369,312 · 1
R03$162,000 · 1

Top collaborators

Others in their field

Top investigators on “Malignant Neoplasms”

Research focus

Malignant NeoplasmsSouth CarolinaUniversitiesMedicalBaseResourcesTranslational ResearchFundingCommunitiesClinical ResearchBiologicalServicesChargeCohortResearch PersonnelDesignCancer CenterInsightClinical TrialsResearch Project GrantsChronic DiseaseProgramsLinkClinic

Grant awards (25)

Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer$370,628
R01 · FY2022 · CA
CDK8/19 inhibitors for therapy of advanced prostate cancer$846,340
R44 · FY2021 · CA
Medical University of South Carolina Transdisciplinary Collaborative Center in Precision Medicine and Minority Men's Health$1,325,883
U54 · FY2020 · MD
CDK8/19 inhibitors for therapy of advanced prostate cancer$1,130,935
R44 · FY2020 · CA
Medical University of South Carolina Transdisciplinary Collaborative Center in Precision Medicine and Minority Men's Health$240,050
U54 · FY2020 · MD
Medical University of South Carolina Transdisciplinary Collaborative Center in Precision Medicine and Minority Men's Health$1,594,338
U54 · FY2019 · MD
MUSC/HCC Paul Calabresi Clinical Oncology Career Development Program$244,971
K12 · FY2019 · CA · contact PI
A Phase 1b Trial of Oligomeric Procyanidin Complex in Combination with Metformin for Reduced AGE Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy$72,216
U54 · FY2019 · CA · contact PI
Medical University of South Carolina Transdisciplinary Collaborative Center in Precision Medicine and Minority Men's Health$1,571,747
U54 · FY2018 · MD
MUSC/HCC Paul Calabresi Clinical Oncology Career Development Program$575,994
K12 · FY2018 · CA · contact PI
A Phase 1b Trial of Oligomeric Procyanidin Complex in Combination with Metformin for Reduced AGE Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy$74,450
U54 · FY2018 · CA · contact PI
Medical University of South Carolina Transdisciplinary Collaborative Center in Precision Medicine and Minority Men's Health$1,594,338
U54 · FY2017 · MD
MUSC/HCC Paul Calabresi Clinical Oncology Training Program Plan$537,059
K12 · FY2017 · CA · contact PI
A Phase 1b Trial of Oligomeric Procyanidin Complex in Combination with Metformin for Reduced AGE Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy$74,450
U54 · FY2017 · CA · contact PI
Medical University of South Carolina Transdisciplinary Collaborative Center in Precision Medicine and Minority Men's Health$1,682,124
U54 · FY2016 · MD
MUSC/HCC Paul Calabresi Clinical Oncology Training Program Plan$537,059
K12 · FY2016 · CA · contact PI
MUSC/HCC Paul Calabresi Clinical Oncology Training Program Plan$537,059
K12 · FY2015 · CA · contact PI
MUSC/HCC Paul Calabresi Clinical Oncology Training Program Plan$368,191
K12 · FY2014 · CA · contact PI
Phase 1 Bioassay-guided Trial of Lycopene and Docetaxel for Prostate Cancer$159,412
R21 · FY2014 · CA · contact PI
Phase 1 Bioassay-guided Trial of Lycopene and Docetaxel for Prostate Cancer$209,900
R21 · FY2013 · CA · contact PI
MUSC/HCC Paul Calabresi Clinical Oncology Training Program Plan$163,782
K12 · FY2013 · CA
Murine model of chronic prostatitis$15,552
P20 · FY2006 · MD · contact PI
MOLECULAR TARGETS OF ANTI-TUMOR NSAIDS$50,070
R03 · FY2005 · CA
MOLECULAR TARGETS OF ANTI-TUMOR NSAIDS$30,930
R03 · FY2005 · CA
MOLECULAR TARGETS OF ANTI-TUMOR NSAIDS$81,000
R03 · FY2004 · CA